Sentences with phrase «cancer gene tests»

Dr. Hill's work has included serving as trial counsel for plaintiffs and defendants in patent infringement suits involving breast and ovarian cancer gene tests, radiology informatics, hospital information systems, orthopedic surgical devices, MRI diffusion tensor imaging, generic drugs in Hatch - Waxman patent litigation, and biologics in suits brought under the Biologics Price Competition and Innovation Act.

Genomics firm 23andMe is the first to receive approval for direct - to - consumer cancer gene tests in the US, but will recipients misunderstand the results?

But as researchers pool data from thousands of cancer gene tests, some of those benign variants may be reclassified as dangerous, or may become informative in ways that hadn't been anticipated.

Not exact matches

At last year's Brainstorm Health conference in San Diego, Bergh found himself sitting at dinner with Othman Laraki, the cofounder and CEO of Color Genomics — a company that extracts the DNA from a customer's submitted saliva sample and then looks for a set number of gene mutations known to be associated with increased risk for developing certain hereditary cancers or heart conditions (depending on the test).

She chose that step because she had been tested and knew she possessed those gene mutations, which put her risk of developing breast cancer at greater than 80 %.

The other, a former White House aide to President Obama, tested positive for the BRCA2 gene mutation that has led to breast cancer in her family for generations — and is taking aggressive steps to avoid the same fate.

By invalidating key parts of Myriad's patents, the court has removed a bar that prevented labs using new technology from developing and selling broader one - time tests that search for all known cancer risks, including the BRCA genes, geneticists said.

The scientists were interested in understanding what factors influenced women to share test results, particularly with their children, who might also be affected by the cancer - conferring genes.

If you have a strong family history of breast cancer or other cancers, your doctor may recommend a blood test to help identify specific mutations in BRCA or other genes that are being passed through your family.

With new tests to identify women who are at heightened risk of breast cancer, new drugs aimed at preventing allergies, and the discovery of new genes that are key to the progression of conditions like Alzheimer's - to give just three examples - we are at the dawn of a whole new era:

The June 13 ruling was a victory for some: By the end of the day, two competitors were offering lower - priced tests for the breast cancer genes.

These findings allowed researchers to create a chimera virus: a mouse virus with a human viral gene that can be used to test molecules that inhibit human LANA protein in an animal model of disease, treating not only human herpes virus infection but also its associated cancers.

To test whether those cancer genes help the cell survive, they tried blocking them.

Recent advances in the understanding of cancer have led to more personalized therapies, such as drugs that target particular proteins and tests that analyze gene expression patterns in tumors to predict a patient's response to therapy.

It has used broad gene patents to operate a monopoly over testing for the two BRCA genes, which when mutated can cause inherited forms of breast cancer.

Since 1994, dozens more genes have been found that increase a woman's risk of hereditary breast cancer, but by how much is uncertain, confounding already complicated issues in genetic testing and counseling.

Myriad Genetics owns the patent over certain breast cancer genes, effectively giving them ownership over any test involving the genes.

Bloch's colleagues at the National Institute of Environmental Health Sciences tested the oils in gene expression studies on lab - grown human breast cancer cells and found that they could mimic estrogens, the primary female sex hormones, and inhibit androgens, the primary male sex hormones.

Since the Lung Cancer Mutation Consortium trial began in 2009, many patients are now tested for mutated or altered genes before treatment.

Federal regulators approved the first direct - to - consumer test for the BRCA genes, which increase the risk of breast and ovarian cancer, the agency announced on Tuesday.

Much like the association between BRCA gene mutation and the risk for breast cancer in women changed the approach to treatment / prevention, the identification of the Kallikrein 6 gene region may change the course of prostate cancer care through a blood test developed by the Lunenfeld - Tanenbaum Research Institute.

«Every woman with breast cancer is now tested for that gene.

Genetic tests for mutations in the so - called breast cancer genes, BRCA1 and BRCA2, may not reveal as much about cancer risk as earlier reports have estimated, according to two studies published in tomorrow's New England Journal of Medicine.

This challenge arose from complaints made initially by breast cancer patients who objected to Myriad's monopoly control over the testing and interpretation of risks associated with these cancer genes.

«In our experiments, our nanoparticles successfully delivered a test gene to brain cancer cells in mice, where it was then turned on,» says Jordan Green, Ph.D., an assistant professor of biomedical engineering and neurosurgery at the Johns Hopkins University School of Medicine.

Women with a family history of two or more immediate family members (mother, sister, daughter) with breast or ovarian cancer or with a positive genetic test for mutations in the BRCA1 or BRCA2 genes may be advised to consider having both breasts removed, because they are at high risk of a new cancer developing in the other breast.

Scientists have developed a three - in - one blood test that could transform treatment of advanced prostate cancer through use of precision drugs designed to target mutations in the BRCA genes.

Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing in the metastatic non-small cell lung cancer (NSCLC) setting in the United States.

They tested these drugs one at a time for lethal interaction with 112 different tumor - suppressor gene mutations in human cancer cells growing in the lab.

Using in vitro, or test tube, experiments, the researchers applied these chemicals to human cancer cells to measure changes of estrogen receptor - and androgen receptor - target genes and transcriptional activity.

Clinical trials of treatments for ovarian and related cancers would benefit from knowledge of patients» gene mutations, but in many trials, the cost of genetic testing is prohibitively expensive, the brief says.

A new study suggest major cancer genes play a bigger role than thought in childhood cancer, potentially influencing surveillance, genetic testing, and treatment.

«The good news is that this finding predicts that patients missing either gene should be sensitive to new therapies targeting focal adhesion enzymes, which are currently being tested in early - stage clinical trials,» says Shaw, who is also a member of the Moores Cancer Center and an adjunct professor at the University of California, San Diego.

This test may be particularly useful for patients with high grade serous ovarian cancer because the mutated cancer gene TP53 is found in more than 99 per cent of patients with this form of the disease.

In the past few years, Vogelstein and Kinzler have shifted away from discovering new cancer genes to a less glamorous pursuit: using genetic tests to detect common tumors as early as possible, when they are easiest to cure.

Further research could test these cancer stem cell gene expression at the RNA and protein level in circulating tumor cells and biopsies from patients on trial.

Using clinical, genetic, and gene expression data as filters to distinguish genes whose copy number alteration causes cancer from those for whom copy number changes are incidental, the team whittled down their list from 14,000 to a more manageable number, each of which they systematically tested using genetic experiments in animals.

Kenwrick assesses the likelihood of an inherited cause by studying the family's genetic tree and medical history, interpreting existing pathology or genetic reports from cancer patients in the family, and offering genetic tests if particular genes seem to be the likely culprits.

In fact, the well - known test for prostate cancer, the PSA test (Prostate Specific Antigen), is based on one of the Kallikrein genes, KLK3.

A study done by researchers at Fox Chase Cancer Center shows that many relatives of patients who undergo testing for a gene linked to breast and ovarian cancers misinterpret the results, and less than half of those who could benefit from genetic testing say they plan to get tested themselves — despite the fact that knowing your genetic status may help catch the disease in its earliest stages.

The researchers also tested how the loss of HSF1 affected mouse cells carrying either of two cancer - inducing mutant genes.

If a woman with a strong family history of breast and ovarian cancers tests negative for the BRCA1 / 2 genes, that does not mean her relatives are not at risk, says Daly — her siblings could still carry the gene, or there could be additional genes present that predispose them to cancer that clinicians don't yet know how to test for.

Mutations in known breast cancer genes such as BRCA1 and BRCA2 are identified in only approximately 20 per cent of women who are offered genetic testing for familial breast cancer.

In tests on human breast cancer cells and in special immunodeficient mice with tissue grafts, the scientists found that both agents interfered with genes involved with breast cancer cell growth, resulting in more cancer cells.

Myriad Genetics has used broad gene patents to operate a monopoly over testing for the two BRCA genes, which when mutated can cause inherited forms of breast cancer.

When Lisbeth Ceriani, a 43 - year - old Massachusetts woman, was diagnosed with breast cancer last year, her doctors recommended that she undergo genetic testing to see if she carried mutations in the BRCA1 and BRCA2 genes that increase risk of breast and ovarian cancers.

Myriad, which licensed the BRCA genes from the University of Utah and others who discovered them, runs a testing service to check for mutations that convey a risk for breast cancer.

Fanta and his team used a commercially available test to analyze levels of the genes ERCC1 and TS in 41 patients with metastatic colorectal cancer.

Most cancers are curable if they are detected early, and the researchers are exploring ways to use cancer gene discoveries to develop cancer screening tests to improve cancer survival.

The researchers found that over 25 percent of index patients with normal results from commercial testing of BRCA1 and BRCA2, but with families severely affected by breast cancer, could be resolved by sequencing all genes known to be involved in breast cancer.